B. Braun News

Indonesian Minister of Health launches new German pharmaceutical factory in Karawang

The Minister of Health of the Republic of Indonesia, Prof. Dr. Dr. Nila Djuwita F. Moeloek, officially launched the new pharmaceutical factory of PT B. Braun Medical Indonesia in Karawang today, which will produce innovative infusion solution products to meet the needs of domestic and export markets.

Bukit Indah - Karawang. Built on an area of 19 hectares with an investment value of close to IDR 900 billion, the factory will become a key production site for B. Braun, a leading global medical technology and pharmaceutical company. The factory is equipped with advanced technology to produce high quality and safe medical products.The opening ceremony was also officiated by Member of the Management Board, B. Braun Melsungen and President of B. Braun Asia Pacific, Anna Maria Braun; Head of the Food and Drug Supervisory Agency (BPOM), Mrs. Ir. Penny Kusumastuti Lukito; and the Regent of Karawang, Dr. Cellica Nurrachadiana.

Minister of Health of the Republic of Indonesia, Prof. Dr. dr. Nila Djuwita F. Moeloek, said, “Congratulations to B. Braun for the opening of your new pharmaceutical factory in Indonesia.  I am delighted that this investment will elevate the availability of world class healthcare products and services for our citizens, support the efforts of the government to provide good health system services; as well as boost Indonesia’s socio-economic growth as an exporter of pharmaceutical solutions.” 

President of B. Braun Asia Pacific, Ms. Anna Maria Braun, said, “For 178 years, B. Braun has lived its vision to protect and improve the health of people around the world.  We have been serving the people of Indonesia with our products and services for close to 40  years and today, we are proud to continue our commitment to this country and its people by building this pharmaceutical factory, which will become a key pharmaceutical production site in the Asia Pacific region. B. Braun wishes to fully support the aspirations of the National Health Insurance (JKN) to provide world class and affordable medical products for the people of Indonesia. “

B. Braun’s investment in its latest production plant is in line with the Presidential Instruction No. 6 of 2016 on Acceleration of Pharmaceutical Industry and Medical Instruments and the Minister of Health Regulation No. 17/2017 on the Action Plan for the Development of Pharmaceutical and Medical Devices in Indonesia. As the new production plant begins to operate, Indonesia will be able to minimize its dependency on imported products and may even transform itself into an exporter country, capable of anticipating medicinal shortages in the future.

The construction of the factory will be completed in two phases. The production plant’s annual production capacity shall reach 15 million units in the first phase and progress to an annual production capacity of 48 million units upon entering the second phase of construction.  These infusion solutions and injectable medicines will cater to the needs of patients in Indonesia and be exported to other countries in the Asia Pacific region.  

Infusion Solutions are one of the basic treatments administered to patients. B. Braun manufactures infusion solutions in a closed system container, which reduces the risk of air, bacterial and non-bacterial contamination. Some of the products, which will be manufactured at the new factory, are Ecosol Ringer Lactate, Sterofundin ISO, Ecosol Sodium Chloride 0.9%, Ecosol Glucose 5% and Ecosol Glucose 10%.   

About B.Braun

With over 60,000 employees in 64 countries, B. Braun is a leading global healthcare company specializing in solutions related to infusion therapy, orthopaedics, neurosurgery, anaesthesia, extracorporeal blood treatment, spine surgery, diabetes care, clinical nutrition, wound management, infection prevention and surgical technologies.  In 2016, B. Braun achieved third party sales of 6.47 billion Euros.   

In Indonesia, B. Braun owns two legal entities, which are B. Braun Medical Indonesia, the country office in Jakarta; and B. Braun Pharmaceutical Indonesia, its manufacturing site in Karawang, West Java.  B. Braun Medical Indonesia is involved in the marketing and distributing of medical devices and pharmaceutical products. Its sales offices are present throughout the country and it prides itself in playing a key role in educating and training healthcare professionals in keeping with its vision to improve healthcare throughout Indonesia.

For more information please contact :

Enny Indrayanti
Human Resource &
Corporate Communications Director
B. Braun Medical Indonesia
Ph : +62 21 52907177
E : enny.indrayanti@bbraun.com

Matej Gaspar
Inke Maris & Associates
Communications Consultant
for B.Braun Medical Indonesia
Ph : +62 21 828 1250
E : matej.gaspar@inkemaris.com